Medscape

Squaring Genetic vs Clinical Findings in Familial Polyposis

Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are found to ...
Monthly Prescribing Reference

Investigational Oral Therapy Fast Tracked for Familial Adenomatous Polyposis

Familial adenomatous polyposis is caused by abnormalities in the APC gene. The Food and Drug Administration (FDA) has granted Fast Track designation to REC-4881 for the treatment of familial ...
Science Daily

Colon cancer: How mutation of the APC gene disrupts lymphocyte migration

In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC gene induce the formation of intestinal polyps, but also reduce immune system ...
Monthly Prescribing Reference

Dual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...
ascopubs.org

Compliance with NCCN screening and chemoprevention recommendations among carriers of deleterious mutations in the adenomatous polyposis coli gene.

Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy.
Nasdaq

FDA Grants Fast Track Designation To Biodexa's ERapa For Familial Adenomatous Polyposis

(RTTNews) - Biodexa Pharmaceuticals PLC (BDRX), a clinical-stage biopharmaceutical company, announced on Monday that its lead drug candidate, eRapa, has been granted Fast Track Designation by the U.S.